Status:
COMPLETED
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Lead Sponsor:
Organon and Co
Conditions:
Migraine Headache
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo. The long term extension study whic...
Eligibility Criteria
Inclusion
- Patient had at least a 6-month history of migraine, with or without aura
- Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions
- Patient was judged to be in good health, apart from migraine
Exclusion
- Patient was pregnant or a nursing mother
- Patient had abused drugs or alcohol within 12 months prior to entering the study
- Patient had a history of cardiovascular disease
- Patient had clinically significant ECG abnormality
- Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening
- Patient received treatment with an investigational device or compound within 30 days of the study start
- Patient typically suffered from less then 1 or more than 8 attacks of migraine per month
- Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches
- Patient had prior exposure to rizatriptan
Key Trial Info
Start Date :
March 1 1995
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 1996
Estimated Enrollment :
1473 Patients enrolled
Trial Details
Trial ID
NCT00897949
Start Date
March 1 1995
End Date
July 1 1996
Last Update
February 3 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.